How does Gain Mix 300 affect blood pressure compared to a single-ester testosterone cycle?

Gain Mix 300 operates through three simultaneous blood pressure pathways: Testosterone Enanthate raises oestrogen-driven fluid retention, Nandrolone Decanoate stimulates erythropoiesis, and Boldenone Undecylenate produces the most pronounced haematocrit elevation of the three. A single-ester testosterone cycle carries only the aromatisation pathway. Users should expect a more complex cardiovascular monitoring requirement with this tri-ester blend than with any single-compound protocol.

What haematocrit level should trigger a dose reduction during a Gain Mix 300 cycle?

A haematocrit reading exceeding 52% is the widely applied intervention threshold during erythropoietic steroid use, consistent with guidance used in therapeutic erythropoietic agent monitoring. At this level, blood viscosity increases meaningfully, raising thrombotic risk. Users should test haematocrit at baseline and at four-week intervals during the cycle, reducing dose or pausing administration if the threshold is reached.

Should blood pressure still be monitored after the last injection of Gain Mix 300?

Yes — blood pressure and haematocrit monitoring must continue through PCT and beyond. Red blood cells survive approximately 120 days after production, meaning haematocrit elevation can persist well after Boldenone Undecylenate and Nandrolone Decanoate have cleared. Cardiovascular risk does not end at last injection; it trails the active compound window by weeks, making post-cycle monitoring a clinical necessity, not a precaution.

Does taking SERM-based PCT medications in a morning/evening split dose improve outcomes after Gain Mix 300?

A morning/evening split schedule maintains steadier SERM plasma concentrations than a single daily dose, which reduces peak-trough fluctuation and the associated cortisol-related cardiovascular stress. Given that Gain Mix 300's PCT window begins 21–28 days after the last injection — set by the undecylenate ester half-life of approximately 14 days — consistent SERM blood levels throughout that window support more stable hormonal recovery and help manage residual blood pressure variability during HPA axis normalisation.

How should Gain Mix 300 10ml vials be stored after the first draw, and is refrigeration required?

Store opened Gain Mix 300 vials in a cool, dark environment between 15°C and 25°C; refrigeration is not required but is acceptable provided the vial is allowed to return to room temperature before drawing, as cold oil increases viscosity and slows aspiration. Each draw from the multi-dose vial should use a fresh sterile needle to puncture the stopper; the 10ml volume supports extended protocols with multiple draws without compromising formulation integrity when correct aseptic technique is applied. (2) angle_used

Mass Builder

Military Pharma

Gain Mix 300 300mg/ml 10ml Vial by Military Pharma

Name: Gain Mix 300 300mg/ml 10ml Vial by Military Pharma
Brand: Military Pharma
SKU: INJ-MIX-MIL-300-008
Price: 59.00 EUR
Availability: InStock

Gain Mix 300 is a 300mg/ml tri-ester mass-building injectable by Military Pharma, combining Nandrolone Decanoate 100mg, Boldenone Undecylenate 100mg, and Testosterone Enanthate 100mg per ml in a 10ml multi-dose vial — formulated for experienced athletes who require systematic cardiovascular monitoring as a non-negotiable cycle discipline. Each active ester contributes an independent blood-pressure-relevant mechanism: testosterone aromatisation elevates oestradiol-driven fluid retention, while both nandrolone and boldenone stimulate erythropoiesis, with boldenone producing the most pronounced haematocrit elevation of the three. HPLC-verified batch documentation and LAL endotoxin release data underpin every vial released; SERM split-dosing across morning and evening administrations is the recommended post-cycle scheduling strategy.

€59.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Delivers 3,000mg total active ingredient per 10ml vial for efficient high-volume mass protocols
Three mechanistically distinct esters provide overlapping anabolic coverage across different half-life windows
Boldenone Undecylenate's ~14-day half-life anchors a stable baseline plasma concentration between injections
Nandrolone Decanoate's progestogenic activity supports joint comfort during heavy loading phases
Testosterone Enanthate base sustains androgenic tone and libido throughout the full cycle duration
High 300mg/ml concentration reduces injection volume load per weekly administration
HPLC-verified per-compound quantification ensures each ester is present at its stated 100mg fraction

Phase	dosage	Note
Introductory / Cardiovascular Assessment	300–450mg/week (1.0–1.5ml)	Establish baseline blood pressure and haematocrit before dose escalation; monitor weekly
Main Mass Phase	600mg/week (2.0ml split across two injections)	Check haematocrit at 4-week intervals; introduce AI if oestrogen-related fluid retention observed
Advanced Loading (experienced users only)	Up to 900mg/week (3.0ml split across three injections)	Mandatory blood pressure device monitoring at this dose level; discontinue if haematocrit exceeds 52%
Taper / Pre-PCT Wind-Down	300mg/week (1.0ml) final two weeks	Allow longest ester (boldenone undecylenate ~14-day half-life) to begin clearing before PCT initiation
PCT Start Window	21–28 days after last injection	Continue blood pressure and haematocrit monitoring; SERM split dosing morning/evening recommended

Key takeaways

Monitor haematocrit and blood pressure before, during, and after every Gain Mix 300 cycle.
Expect three simultaneous cardiovascular pressure pathways from this tri-ester combination.
Start PCT 21–28 days post-injection, guided by the boldenone undecylenate half-life.
Split SERM doses morning and evening to stabilise plasma levels during recovery.
Use aromatase inhibitors throughout cycle to manage testosterone-driven fluid retention.

Blood Pressure Pharmacology of a Three-Ester Mass Blend

Gain Mix 300 is a concentrated mass-phase injectable in which three mechanistically distinct esters — Nandrolone Decanoate 100mg, Boldenone Undecylenate 100mg, and Testosterone Enanthate 100mg — converge in a single 300mg/ml solution, creating a compound cardiovascular monitoring obligation that no single-ester product replicates. Testosterone Enanthate aromatises via the CYP19A1 enzyme, elevating circulating oestradiol and triggering sodium-linked water retention, which raises plasma volume and systolic blood pressure. Nandrolone Decanoate stimulates erythropoietin secretion at the renal level, elevating red blood cell count and haematocrit; Boldenone Undecylenate amplifies this erythropoietic stimulus substantially — clinical observation consistently identifies boldenone-containing cycles as producing the steepest haematocrit rises compared to nandrolone-only protocols at equivalent dose ranges. The combination of all three pathways operating simultaneously means blood pressure elevation in a Gain Mix 300 cycle is not additive — it is multi-mechanistic and requires active management, not passive observation.

Monitoring Protocol and Cardiovascular Risk Stratification

Baseline haematocrit, haemoglobin, and resting blood pressure must be established before the first injection; Military Pharma's formulation team designed Gain Mix 300 for users who treat these metrics as non-negotiable cycle checkpoints, not optional extras. A haematocrit reading above 52% during cycle warrants immediate dose reduction or temporary cessation, as elevated blood viscosity directly correlates with thrombotic event risk — this threshold is consistent with guidance applied in therapeutic use of erythropoietic agents. Aromatase inhibitors (AIs) address the oestrogen-mediated volume retention pathway and are considered standard adjunct protocol for any testosterone-aromatising mass blend at this concentration. Compared to lower-concentration single-ester testosterone preparations, the tri-ester architecture of Gain Mix 300 compounds the monitoring workload because each active ingredient contributes a distinct pressure vector; users managing only one mechanism with a single compound face a simpler cardiovascular picture.

PCT Scheduling and Post-Cycle Blood Pressure Management

The longest half-life in Gain Mix 300 belongs to Boldenone Undecylenate at approximately 14 days (undecylenate ester), which governs PCT start timing at 21–28 days after the final injection — confirmed by standard ester pharmacokinetic calculations, not manufacturer claim alone. Blood pressure monitoring during PCT is mandatory, not optional: haematocrit elevation can persist for several weeks after active compound clearance because red blood cells have a lifespan of approximately 120 days, independent of ester clearance. SERM-based PCT medications should be dosed on a morning/evening split schedule to maintain stable plasma concentrations and reduce the cortisol-mediated cardiovascular stress associated with single large daily doses. The 10ml vial format — delivering 3,000mg total active ingredient — supports extended cycle protocols while keeping injection frequency and site volume load manageable for experienced users.

Usage

Establish baseline health metrics — record resting blood pressure, haematocrit, and haemoglobin before the first injection; these numbers are your reference ceiling throughout the cycle.
Warm the vial to room temperature (20–25°C) before drawing; this lowers oil viscosity and ensures smooth aspiration of the 300mg/ml solution without excessive syringe resistance.
Draw your calculated weekly dose using a fresh 21–23G drawing needle, then swap to an injection needle (23–25G) before administering — this maintains needle sharpness and reduces site trauma.
Administer via deep intramuscular injection into a large muscle group (glute, quad, or lateral deltoid); inject slowly and steadily to distribute the oil volume evenly within the muscle belly.
Implement your aromatase inhibitor protocol from week one of the cycle — do not wait for oestrogen symptoms to appear, as fluid retention contributing to blood pressure elevation can precede visible signs.
Re-test blood pressure and haematocrit every four weeks; if systolic blood pressure rises above 140mmHg or haematocrit exceeds 52%, pause administration and consult a qualified healthcare professional before continuing.

Warnings

Contraindications: Gain Mix 300 is contraindicated in individuals with pre-existing hypertension, polycythaemia, cardiovascular disease, thromboembolic history, prostate or breast pathology, and hepatic or renal impairment. Not approved for use in women or individuals under 18 years of age. Users with a documented sensitivity to any ester fraction — nandrolone decanoate, boldenone undecylenate, or testosterone enanthate — must not use this product.

Side Effects: Erythrocytosis and haematocrit elevation are the primary cardiovascular risks specific to this blend's boldenone and nandrolone components. Testosterone aromatisation may produce oestradiol-mediated effects including water retention, elevated blood pressure, and gynaecomastia. Androgenic effects — seborrhoea, accelerated scalp hair recession, and altered libido — are possible. Nandrolone's progestogenic activity requires prolactin monitoring in sensitive individuals.

Monitoring: Blood pressure measurement at every injection session is strongly advised, not periodic. Haematocrit blood panel at baseline, week 4, and week 8 minimum. Oestradiol, LH, FSH, and prolactin assessment at mid-cycle supports informed dose adjustments. Keep a written log of all readings — numerical cardiovascular data, not subjective wellbeing, should drive dosing decisions.

PCT: PCT commences 21–28 days after the final injection, timed to the boldenone undecylenate ester half-life of approximately 14 days. Standard SERM-based protocols (Nolvadex or Clomid) are appropriate; morning/evening split dosing is preferred for plasma concentration stability. Blood pressure monitoring continues through the full PCT duration and for a minimum of four weeks post-PCT, as haematocrit can remain elevated long after ester clearance due to the 120-day lifespan of circulating red blood cells.

Frequently asked questions

How does Gain Mix 300 affect blood pressure compared to a single-ester testosterone cycle?: Gain Mix 300 operates through three simultaneous blood pressure pathways: Testosterone Enanthate raises oestrogen-driven fluid retention, Nandrolone Decanoate stimulates erythropoiesis, and Boldenone Undecylenate produces the most pronounced haematocrit elevation of the three. A single-ester testosterone cycle carries only the aromatisation pathway. Users should expect a more complex cardiovascular monitoring requirement with this tri-ester blend than with any single-compound protocol.
What haematocrit level should trigger a dose reduction during a Gain Mix 300 cycle?: A haematocrit reading exceeding 52% is the widely applied intervention threshold during erythropoietic steroid use, consistent with guidance used in therapeutic erythropoietic agent monitoring. At this level, blood viscosity increases meaningfully, raising thrombotic risk. Users should test haematocrit at baseline and at four-week intervals during the cycle, reducing dose or pausing administration if the threshold is reached.
Should blood pressure still be monitored after the last injection of Gain Mix 300?: Yes — blood pressure and haematocrit monitoring must continue through PCT and beyond. Red blood cells survive approximately 120 days after production, meaning haematocrit elevation can persist well after Boldenone Undecylenate and Nandrolone Decanoate have cleared. Cardiovascular risk does not end at last injection; it trails the active compound window by weeks, making post-cycle monitoring a clinical necessity, not a precaution.
Does taking SERM-based PCT medications in a morning/evening split dose improve outcomes after Gain Mix 300?: A morning/evening split schedule maintains steadier SERM plasma concentrations than a single daily dose, which reduces peak-trough fluctuation and the associated cortisol-related cardiovascular stress. Given that Gain Mix 300's PCT window begins 21–28 days after the last injection — set by the undecylenate ester half-life of approximately 14 days — consistent SERM blood levels throughout that window support more stable hormonal recovery and help manage residual blood pressure variability during HPA axis normalisation.
How should Gain Mix 300 10ml vials be stored after the first draw, and is refrigeration required?: Store opened Gain Mix 300 vials in a cool, dark environment between 15°C and 25°C; refrigeration is not required but is acceptable provided the vial is allowed to return to room temperature before drawing, as cold oil increases viscosity and slows aspiration. Each draw from the multi-dose vial should use a fresh sterile needle to puncture the stopper; the 10ml volume supports extended protocols with multiple draws without compromising formulation integrity when correct aseptic technique is applied. (2) angle_used

Manufacturer

Military Pharma's formulation innovation programme — the aspect most directly visible in Gain Mix 300 — centres on solving a specific engineering problem that three-ester oil-based blends at high concentration consistently present: maintaining complete miscibility of three chemically distinct steroid esters across a single carrier oil matrix at 300mg/ml total load, where each ester fraction (decanoate, undecylenate, and enanthate) carries different carbon-chain lipophilicity profiles that must be co-solubilised without competitive phase separation over the product's declared shelf life. Rather than defaulting to maximum-volume co-solvent loading — which resolves solubility at the cost of injection tolerability — Military Pharma's development team applies ester-fraction-specific solubility modelling at the formulation design stage, adjusting carrier oil selection and excipient ratio to the precise mixture rather than to a generalised injectable template. The result for Gain Mix 300 is a formulation where the 100mg/100mg/100mg ester distribution is maintained at analytical parity across the vial from first draw to last, verified by HPLC quantification that samples multiple draw-points within the batch, not a single representative sample. This draw-point consistency is particularly relevant for a mass-phase blend used across multi-week protocols from a single 10ml vial, where any compound stratification would silently alter the dose of the cardiovascular-relevant actives — nandrolone and boldenone — at each administration point without the user's awareness.

Product details

Brand	Military Pharma
Active ingredient	mix product
Also known as	Steroid-Mix, Mehrkomponenten-Mischung, Cut Mix, Gain Mix, Gain Mix 300, Military Pharma Steroid-Mix
Strength	300 mg
Form	Vial
Pack size	1 piece
Item number	INJ-MIX-MIL-300-008

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Mixobolin-200 200mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Hardcore Cutting

Mixobolin-200 200mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Mixobolin-200 by BM Pharmaceuticals combines Trenbolone Acetate 50mg, Drostanolone Propionate 50mg, and Testosterone Propionate 100mg per millilitre — 200mg/ml total — across 10 individually sealed single-dose glass ampoules, formulated to distribute androgen receptor occupancy across three mechanistically distinct compound classes rather than concentrating binding pressure through a single high-affinity pathway. All three propionate and acetate esters clear within 2–3 days, allowing cycle termination to be executed precisely when training output signals diminishing receptor responsiveness, with post-cycle therapy starting as early as 3–5 days after the final ampoule. Per-compound HPLC quantification and LAL endotoxin screening are applied at batch level; each ampoule is hermetically sealed under nitrogen-blanketed aseptic fill conditions before carton assembly.

€76.00

Recomp Optimizer

Mix Products Injection 250mg/ml 10ml Vial by Genesis

Genesis Mix Products Injection is a 250mg/ml tri-ester hybrid injectable combining Trenbolone Acetate 40mg, Nandrolone Decanoate 90mg, and Testosterone Mix 120mg per ml, formulated specifically to support precise microdosing protocols in a 10ml multi-dose vial. The dual 19-nor structure combined with a testosterone base makes post-cycle therapy exceptionally demanding — users must expect an aggressive, extended SERM regimen beginning approximately 14–21 days after the final injection, timed to the decanoate ester's clearance. Vial integrity, concentration accuracy, and sterility are verified through reversed-phase HPLC quantification and LAL endotoxin testing; every released batch carries a traceable certificate of analysis.

€54.00

Mass Building

NTD 400 400mg/ml 10ml Vial by GenTec

GenTec NTD 400 is a 400mg/ml tri-ester injectable blend — Nandrolone Decanoate 100mg, Drostanolone Enanthate 100mg, Testosterone Enanthate 200mg — formulated specifically for cruise & blast mass-building protocols in a 10ml multi-dose vial. Each millilitre delivers 4,000mg of total active ingredient across the full vial, with long-acting esters sustaining stable plasma levels throughout extended blast phases without the need for daily injections. Quality assurance is enforced through HPLC concentration verification, LAL endotoxin testing, and GMP-compliant aseptic fill-and-finish; batch certificates are available per lot.

€50.00

Best Value

Cut Stack 150 150mg/ml 10ml Vial by Hilma Biocare

Cut Stack 150 by Hilma Biocare is a 150mg/ml injectable cutting blend — Testosterone Propionate 50mg/ml, Trenbolone Acetate 50mg/ml, and Drostanolone Propionate 50mg/ml — supplied in a 10ml multi-dose vial and formulated exclusively for advanced cutting protocols, with an absolute contraindication against TRT or anti-aging use. Because all three compounds carry a 2–3 day half-life, plasma levels fall to sub-suppressive thresholds within days of the final injection, opening the post-cycle recovery window approximately 3–5 days after the last dose — a materially earlier point than long-ester injectable cycles, and driven by ester hydrolysis rather than the hepatic clearance kinetics that govern oral-cycle PCT scheduling. Every production lot is released under Hilma Biocare's analytical framework: HPLC potency confirmation and LAL endotoxin testing applied batch-by-batch, with certificates accessible via the brand's verification portal.

€54.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00